Liquidia Corp
LQDA28.040USD
+1.100+4.08%
Fechamento 11/14, 16:00（ET）Cotações atrasadas em 15 min
2.43BValor de mercado
PerdaP/L TTM
Mais detalhes de Liquidia Corp Empresa
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Informações de Liquidia Corp
Código da empresaLQDA
Nome da EmpresaLiquidia Corp
Data de listagemJul 26, 2018
CEODr. Roger A. Jeffs, Ph.D.
Número de funcionários157
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 26
Endereço419 Davis Drive
CidadeMORRISVILLE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal27560
Telefone19193284400
Sitehttps://www.liquidia.com/
Código da empresaLQDA
Data de listagemJul 26, 2018
CEODr. Roger A. Jeffs, Ph.D.
Executivos da empresa Liquidia Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.11M
-0.30%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
365.84K
-1.10%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
169.42K
-29.64%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
143.78K
-1.23%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
142.35K
+1.44%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
85.98K
-6.32%
Mr. Damian Degoa
Mr. Damian Degoa
Independent Director
Independent Director
66.11K
+38.55%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
50.40K
+57.49%
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
18.40K
--
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
13.40K
-27.18%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.11M
-0.30%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
365.84K
-1.10%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
169.42K
-29.64%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
143.78K
-1.23%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
142.35K
+1.44%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
85.98K
-6.32%
Detalhamento da receita
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
14.00M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: há 23 horas
Atualizado em: há 23 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Caligan Partners, LP
9.33%
Farallon Capital Management, L.L.C.
7.85%
Manning (Paul B.)
7.09%
BlackRock Institutional Trust Company, N.A.
5.25%
The Vanguard Group, Inc.
4.54%
Outro
65.94%
Investidores
Investidores
Proporção
Caligan Partners, LP
9.33%
Farallon Capital Management, L.L.C.
7.85%
Manning (Paul B.)
7.09%
BlackRock Institutional Trust Company, N.A.
5.25%
The Vanguard Group, Inc.
4.54%
Outro
65.94%
Tipos de investidores
Investidores
Proporção
Hedge Fund
36.10%
Investment Advisor
16.71%
Investment Advisor/Hedge Fund
12.07%
Individual Investor
11.15%
Research Firm
4.04%
Corporation
2.64%
Family Office
1.88%
Private Equity
0.56%
Bank and Trust
0.44%
Outro
14.42%
Participação acionária institucional
Atualizado em: dom, 5 de out
Atualizado em: dom, 5 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
358
61.00M
70.12%
+1.28M
2025Q2
350
67.92M
79.46%
-5.32M
2025Q1
356
67.75M
79.47%
-4.91M
2024Q4
344
63.62M
75.17%
-10.09M
2024Q3
335
73.31M
89.39%
+16.42M
2024Q2
318
66.67M
87.88%
+4.98M
2024Q1
302
59.34M
79.61%
+7.64M
2023Q4
256
48.15M
70.41%
+4.56M
2023Q3
236
40.52M
62.49%
-5.87M
2023Q2
223
41.12M
63.56%
-6.16M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Caligan Partners, LP
8.12M
9.43%
+300.00
+0.00%
Jun 30, 2025
Farallon Capital Management, L.L.C.
6.83M
7.94%
+2.59M
+61.19%
Jul 07, 2025
Manning (Paul B.)
6.16M
7.21%
+18.40K
+0.30%
Jun 17, 2025
BlackRock Institutional Trust Company, N.A.
4.26M
4.95%
+65.79K
+1.57%
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
4.16%
+126.92K
+3.68%
Jun 30, 2025
Findell Capital Management LLC
3.00M
3.48%
+110.00K
+3.81%
Jun 30, 2025
Opaleye Management Inc.
2.48M
2.87%
+215.00K
+9.51%
Jun 30, 2025
Goldman Sachs & Company, Inc.
2.34M
2.72%
+1.56M
+200.35%
Jun 30, 2025
Jeffs (Roger A)
2.12M
2.46%
-6.42K
-0.30%
Jul 14, 2025
Legend Aggregator LP
1.86M
2.16%
-5.32M
-74.10%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
SPDR S&P Pharmaceuticals ETF
2%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.5%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
1.09%
iShares U.S. Pharmaceuticals ETF
0.57%
Federated Hermes MDT Small Cap Core ETF
0.38%
iShares Micro-Cap ETF
0.28%
SPDR S&P Kensho New Economies Composite ETF
0.26%
Vanguard US Momentum Factor ETF
0.12%
iShares Russell 2000 Growth ETF
0.09%
Ver Mais
SPDR S&P Pharmaceuticals ETF
Proporção2%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.5%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.09%
iShares U.S. Pharmaceuticals ETF
Proporção0.57%
Federated Hermes MDT Small Cap Core ETF
Proporção0.38%
iShares Micro-Cap ETF
Proporção0.28%
SPDR S&P Kensho New Economies Composite ETF
Proporção0.26%
Vanguard US Momentum Factor ETF
Proporção0.12%
iShares Russell 2000 Growth ETF
Proporção0.09%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
